The drug program for wet form of AMD – the effectiveness of treatments based on diagnostics tests and patients opinion Original research study
Article Sidebar
Published:
Jan 5, 2021
Keywords:
wet form of AMD, drug program, ranibizumab, aflibercept, visual acuity
Main Article Content
Abstract
In people over 45 AMD is considered main reason for decrease in acuity of vision and blindness (amaurosis/ablepsia/typhlosis). The wAMD treating may require an immediate using of anti-VEGF eye injections (into the vitreous cavity). The AMD treatment program with ranibizumab and aflibercept has been available in Poland since 2015. The research aim was to evaluate the efficiency of the AMD treatment program in 98 patients participated in the AMD treatment program. Patients have been examined using diagnostic trials and diagnostic survey.
Downloads
Download data is not yet available.
Article Details
How to Cite
1.
Michalik-Marcinkowska U, Jas I, Misiak A, Dobrowolski D. The drug program for wet form of AMD – the effectiveness of treatments based on diagnostics tests and patients opinion. Ophthatherapy [Internet]. 2021Jan.5 [cited 2024Apr.19];8(1):11-8. Available from: https://journalsmededu.pl/index.php/ophthatherapy/article/view/1124
Issue
Section
Conservative treatment
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
Copyright: © Medical Education sp. z o.o. License allowing third parties to copy and redistribute the material in any medium or format and to remix, transform, and build upon the material, provided the original work is properly cited and states its license.
Address reprint requests to: Medical Education, Marcin Kuźma (marcin.kuzma@mededu.pl)
References
1. Wylęgała E, Teper S, Piłat J. Zwyrodnienie plamki związane z wiekiem. Górnicki Wydawnictwo Medyczne, Wrocław 2011.
2. Bandello F, Silva R. AMD age related macular degeneration. Uniwersytet Bordoux 2010.
3. Wong WL, Su X, Li X et al. Global prevalence of age-related macular degeneration and disease burden projection for 2020 and 2040: a systematic review and meta-analysis. Lancet Glob Health. 2014; 2(2): e106-e16.
4. Retina Forum – Test Amslera. http://retina-forum.pl/amsler.html (access: 24.08.2020).
5. Niżankowska MH. Podstawy okulistyki. Volumed, Wrocław 2000.
6. Bhutto I, Lutty G. Understanding age-related macular degeneration (AMD): Relationships between the photoreceptor/retinal pigment epithelium/Bruch’s membrane/choriocapillaris complex. Mol Aspects Med. 2012; 33(4): 295-317.
7. Coleman HR, Chan C, Iii FLF et al. Age-related macular degeneration. Lancet. 2009; 372(9652): 1835-45.
8. Kański J, Milewski SA. Choroby plamki. Górnicki Wydawnictwo Medyczne, Wrocław 2003.
9. Spalton DJ, Hitchings RA, Hunter PA. Atlas of Clinical Ophthalmology. Elsevier, 2004.
10. Gass JD. Stereoscopic atlas of macular diseases. Vol I. Mosby Company, St. Louis 1987.
11. Program lekowy: Leczenie neowaskularnej (wysiękowej) postaci zwyrodnienia plamki związanego z wiekiem (AMD) (ICD10-H.35.3). http://retinaamd.org.pl/wp-content/uploads/2017/01/program-lekowy-kryteria-od-01.01.2017.pdf załącznik B70 (access: 24.08.2020).
12. Teper SJ, Nowińska A, Piłat J et al. Involvement of genetic factors in the response to a variable-dosing ranibizumab treatment regimen for age-related macular degeneration. Mol Vis. 2010; 16: 2598-604.
13. Park K, Amano H, Ito Y et al. Vascular endothelial growth factor receptor 1 (VEGFR1) tyrosine kinase signaling facilitates granulation tissue formation with recruitment of VEGFR1 + cells from bone marrow. Anat Sci Int. 2018; 93(3): 372-83.
14. Yuzawa M, Fujita K, Tanaka E et.al. Assessing quality of life in the treatment of patients with age-related macular degeneration: clinical research findings and recommendations for clinical practice. Clin Ophthalmol. 2013; 7: 1325-32.
15. Brzuzy G. Uszkodzenie wzroku a poczucie jakości życia. Transdyscyp Stud Kult Eduk. 2008; 3: 137-50.
16. Czerwińska K, Kucharczyk I. Niepełnosprawność. Dyskursy Pedagogiki Specjalnej. 2019; 34: 108.
17. Senra H, Ali Z, Balaskas K et al. Psychological impact of anti-VEGF treatments for wet macular degeneration-a review. Graefes Arch Clin Exp Ophthalmol. 2016; 254(10): 1873-80.
18. Okunrintemi V, Valero-Elizondo J, Patrick B et al. Gender Differences in Patient-Reported Outcomes Among Adults With Atherosclerotic Cardiovascular Disease. J Am Heart Assoc. 2018; 7(24): e010498.
19. Bener A, Ghuloum S. Gender difference on patients' satisfaction and expectation towards mental health care. Niger J Clin Pract. 2013; 16: 285-91.
20. Centis E, Trento M, Dei Cas A et al. Stage of change and motivation to healthy diet and habitual physical activity in type 2 diabetes. Acta Diabetol. 2014; 51(4): 559-66.
21. Bucholz EM, Krumholz HM. Women in clinical research: What we need for progress. Circ Cardiovasc Qual Outcomes. 2015; 8(201): S1-S3.
22. Taranowicz I. Rola rodziny w opiece nad człowiekiem przewlekle chorym. Roczniki Socjologii Rodziny, UAM 2001; XIII: 209-28.
23. Vukicevic M, Heraghty J, Cummins R et al. Caregiver perceptions about the impact of caring for patients with wet age-related macular degeneration. Eye (Lond). 2016; 30(3): 413-21.
2. Bandello F, Silva R. AMD age related macular degeneration. Uniwersytet Bordoux 2010.
3. Wong WL, Su X, Li X et al. Global prevalence of age-related macular degeneration and disease burden projection for 2020 and 2040: a systematic review and meta-analysis. Lancet Glob Health. 2014; 2(2): e106-e16.
4. Retina Forum – Test Amslera. http://retina-forum.pl/amsler.html (access: 24.08.2020).
5. Niżankowska MH. Podstawy okulistyki. Volumed, Wrocław 2000.
6. Bhutto I, Lutty G. Understanding age-related macular degeneration (AMD): Relationships between the photoreceptor/retinal pigment epithelium/Bruch’s membrane/choriocapillaris complex. Mol Aspects Med. 2012; 33(4): 295-317.
7. Coleman HR, Chan C, Iii FLF et al. Age-related macular degeneration. Lancet. 2009; 372(9652): 1835-45.
8. Kański J, Milewski SA. Choroby plamki. Górnicki Wydawnictwo Medyczne, Wrocław 2003.
9. Spalton DJ, Hitchings RA, Hunter PA. Atlas of Clinical Ophthalmology. Elsevier, 2004.
10. Gass JD. Stereoscopic atlas of macular diseases. Vol I. Mosby Company, St. Louis 1987.
11. Program lekowy: Leczenie neowaskularnej (wysiękowej) postaci zwyrodnienia plamki związanego z wiekiem (AMD) (ICD10-H.35.3). http://retinaamd.org.pl/wp-content/uploads/2017/01/program-lekowy-kryteria-od-01.01.2017.pdf załącznik B70 (access: 24.08.2020).
12. Teper SJ, Nowińska A, Piłat J et al. Involvement of genetic factors in the response to a variable-dosing ranibizumab treatment regimen for age-related macular degeneration. Mol Vis. 2010; 16: 2598-604.
13. Park K, Amano H, Ito Y et al. Vascular endothelial growth factor receptor 1 (VEGFR1) tyrosine kinase signaling facilitates granulation tissue formation with recruitment of VEGFR1 + cells from bone marrow. Anat Sci Int. 2018; 93(3): 372-83.
14. Yuzawa M, Fujita K, Tanaka E et.al. Assessing quality of life in the treatment of patients with age-related macular degeneration: clinical research findings and recommendations for clinical practice. Clin Ophthalmol. 2013; 7: 1325-32.
15. Brzuzy G. Uszkodzenie wzroku a poczucie jakości życia. Transdyscyp Stud Kult Eduk. 2008; 3: 137-50.
16. Czerwińska K, Kucharczyk I. Niepełnosprawność. Dyskursy Pedagogiki Specjalnej. 2019; 34: 108.
17. Senra H, Ali Z, Balaskas K et al. Psychological impact of anti-VEGF treatments for wet macular degeneration-a review. Graefes Arch Clin Exp Ophthalmol. 2016; 254(10): 1873-80.
18. Okunrintemi V, Valero-Elizondo J, Patrick B et al. Gender Differences in Patient-Reported Outcomes Among Adults With Atherosclerotic Cardiovascular Disease. J Am Heart Assoc. 2018; 7(24): e010498.
19. Bener A, Ghuloum S. Gender difference on patients' satisfaction and expectation towards mental health care. Niger J Clin Pract. 2013; 16: 285-91.
20. Centis E, Trento M, Dei Cas A et al. Stage of change and motivation to healthy diet and habitual physical activity in type 2 diabetes. Acta Diabetol. 2014; 51(4): 559-66.
21. Bucholz EM, Krumholz HM. Women in clinical research: What we need for progress. Circ Cardiovasc Qual Outcomes. 2015; 8(201): S1-S3.
22. Taranowicz I. Rola rodziny w opiece nad człowiekiem przewlekle chorym. Roczniki Socjologii Rodziny, UAM 2001; XIII: 209-28.
23. Vukicevic M, Heraghty J, Cummins R et al. Caregiver perceptions about the impact of caring for patients with wet age-related macular degeneration. Eye (Lond). 2016; 30(3): 413-21.